ketoconazole tablet
a-s medication solutions - ketoconazole (unii: r9400w927i) (ketoconazole - unii:r9400w927i) - ketoconazole tablets are not indicated for treatment of onychomycosis, cutaneous dermatophyte infections, or candida infections. ketoconazole tablets should be used only when other effective antifungal therapy is not available or tolerated and the potential benefits are considered to outweigh the potential risks. ketoconazole tablets are indicated for the treatment of the following systemic fungal infections in patients who have failed or who are intolerant to other therapies: blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis. ketoconazole tablets should not be used for fungal meningitis because it penetrates poorly into the cerebrospinal fluid. coadministration of a number of cyp3a4 substrates such as dofetilide, quinidine cisapride and pimozide is contraindicated with ketoconazole tablets. coadministration with ketoconazole can cause elevated plasma concentrations of these drugs and may increase or prolong both therapeutic and adverse effects to such an extent that
ketoconazole- ketoconazole cream, 2% cream
encube ethicals private limited - ketoconazole (unii: r9400w927i) (ketoconazole - unii:r9400w927i) - ketoconazole cream, 2% is indicated for the topical treatment of tinea corporis, tinea cruris and tinea pedis caused by trichophyton rubrum , t. mentagrophytes and epidermophyton floccosum ; in the treatment of tinea (pityriasis) versicolor caused by malassezia furfur (pityrosporum orbiculare) ; and in the treatment of cutaneous candidiasis caused by candida spp . and in the treatment of seborrheic dermatitis. ketoconazole cream, 2% is contraindicated in persons who have shown hypersensitivity to the active or excipient ingredients of this formulation.
ketoconazole- ketoconazole cream, 2% cream
preferred pharmaceuticals inc. - ketoconazole (unii: r9400w927i) (ketoconazole - unii:r9400w927i) - ketoconazole cream, 2% is indicated for the topical treatment of tinea corporis, tinea cruris and tinea pedis caused by trichophyton rubrum , t. mentagrophytes and epidermophyton floccosum ; in the treatment of tinea (pityriasis) versicolor caused by malassezia furfur (pityrosporum orbiculare) ; and in the treatment of cutaneous candidiasis caused by candida spp . and in the treatment of seborrheic dermatitis. ketoconazole cream, 2% is contraindicated in persons who have shown hypersensitivity to the active or excipient ingredients of this formulation.
ketoconazole- ketoconazole cream, 2% cream
nucare pharmaceuticals,inc. - ketoconazole (unii: r9400w927i) (ketoconazole - unii:r9400w927i) - ketoconazole cream, 2% is indicated for the topical treatment of tinea corporis, tinea cruris and tinea pedis caused by trichophyton rubrum , t. mentagrophytes and epidermophyton floccosum ; in the treatment of tinea (pityriasis) versicolor caused by malassezia furfur (pityrosporum orbiculare) ; and in the treatment of cutaneous candidiasis caused by candida spp . and in the treatment of seborrheic dermatitis. ketoconazole cream, 2% is contraindicated in persons who have shown hypersensitivity to the active or excipient ingredients of this formulation.
ketoconazole hra
hra pharma rare diseases - ketoconazole - cushing syndrome - antimycotics for systemic use - ketoconazole hra is indicated for the treatment of endogenous cushing’s syndrome in adults and adolescents above the age of 12 years.
ketoconazole tablet
a-s medication solutions - ketoconazole (unii: r9400w927i) (ketoconazole - unii:r9400w927i) - ketoconazole tablets are not indicated for treatment of onychomycosis, cutaneous dermatophyte infections, or candida infections. ketoconazole tablets should be used only when other effective antifungal therapy is not available or tolerated and the potential benefits are considered to outweigh the potential risks. ketoconazole tablets are indicated for the treatment of the following systemic fungal infections in patients who have failed or who are intolerant to other therapies: blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis. ketoconazole tablets should not be used for fungal meningitis because it penetrates poorly into the cerebrospinal fluid. coadministration of a number of cyp3a4 substrates such as dofetilide, quinidine, cisapride and pimozide is contraindicated with ketoconazole tablets. coadministration with ketoconazole can cause elevated plasma concentrations of these drugs and may increase or prolong both therapeutic and adverse effects to such an extent tha
ketoconazole tablet
avera mckennan hospital - ketoconazole (unii: r9400w927i) (ketoconazole - unii:r9400w927i) - ketoconazole 200 mg
ketoconazole tablet
bryant ranch prepack - ketoconazole (unii: r9400w927i) (ketoconazole - unii:r9400w927i) - ketoconazole 200 mg
ketoconazole tablet
kaiser foundation hospitals - ketoconazole (unii: r9400w927i) (ketoconazole - unii:r9400w927i) - ketoconazole 200 mg
ketoconazole tablet
havix group inc d-b-a aavis pharmaceuticals - ketoconazole (unii: r9400w927i) (ketoconazole - unii:r9400w927i) - ketoconazole tablets are not indicated for treatment of onychomycosis, cutaneous dermatophyte infections, or candida infections. ketoconazole tablets should be used only when other effective antifungal therapy is not available or tolerated and the potential benefits are considered to outweigh the potential risks. ketoconazole tablets are indicated for the treatment of the following systemic fungal infections in patients who have failed or who are intolerant to other therapies: blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis. ketoconazole tablets should not be used for fungal meningitis because it penetrates poorly into the cerebrospinal fluid. coadministration of a number of cyp3a4 substrates such as dofetilide, quinidine cisapride and pimozide is contraindicated with ketoconazole tablets. coadministration with ketoconazole can cause elevated plasma concentrations of these drugs and may increase or prolong both therapeutic and adverse effects to such an extent that